Bharat Biotech starts voluntary recall of rabies vaccine after batch theft

Company had tested the batch and released it, but part of it was stolen, for which cold chain storage integrity was unknown. Decision made to recall the entire batch

Bharat Biotech, vaccine
Photo: Shutterstock
Sohini Das Mumbai
2 min read Last Updated : Jan 23 2023 | 7:25 PM IST
Hyderabad-based vaccine maker Bharat Biotech on Monday said it has initiated a voluntary recall for a batch of its anti-rabies vaccine Chirorab.

"We have issued a voluntary product recall of a specific batch of Chirorab with batch number 4188. This action was initiated due to the theft of Chirorab from the shipping services provider in Karnataka," the company said in a statement. It added that the company had tested batch No. 4188 and released it, but part of the shipment was stolen, for which cold chain storage conditions are unknown. The action to recall the entire batch has been initiated.

"We are undertaking this voluntary action in accordance with the Principle of Abundant Precaution, keeping patient safety and the public interest in mind," it said.

"The company requests that batch #4188 not be sold and returned to the company. Healthcare providers are requested not to administer Chirorab with batch #4188."

The recall action has been initiated by Chiron Behring Vaccines, which was acquired by Bharat Biotech from GSK in March 2019. In November 2019 Chiron Behring Vaccines re-launched the rabies vaccine Chirorab, which was earlier marketed as Rabipur. The vaccine is manufactured at a WHO-prequalified site in Ankleshwar, Gujarat.

It is an inactivated vaccine used for active pre and post exposure immunisation against rabies. Chirorab is supplied to government hospitals through a tendering process, and also exported to several countries.

The Ankleshwar facility can make 15 million doses of rabies vaccines per year.

In August 2021, Bharat Biotech commercially launched its Covid19 vaccine Covaxin from the Ankleshwar facility. A new filing facility constructed during 2020 was utilized for the production of Covaxin.

The company had deployed multiple production lines at its Hyderabad, Malur, Bengaluru, and Pune campuses to make Covaxin.
  • Part of batch was stolen, cold chain integrity not known
  • Co decided to recall entire batch
  • Rabies vaccine is made at Chiron Behring plant in Ankleshwar
  • Chiron Behring was acquired by Bharat Biotech from GSK in 2019
  • Ankleshwar plant was re-purposed to make Covaxin in 2021

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
Subscribe to Business Standard digital and get complimentary access to The New York Times

Quarterly Starter

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

Save 46%

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Access to Exclusive Premium Stories Online

  • Over 30 behind the paywall stories daily, handpicked by our editors for subscribers

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :Bharat BiotechRabies vaccine

Next Story